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Abstract
Background: Morbidity and mortality following initial survival of cardiac arrest remain high despite great efforts to
improve resuscitation techniques and post-resuscitation care, in part due to the ischemia-reperfusion injury
secondary to the restoration of the blood circulation. Patients resuscitated from cardiac arrest display evidence of
endothelial injury and coagulopathy (hypocoagulability, hyperfibrinolysis), which in associated with poor outcome.
Recent randomized controlled trials have revealed that treatment with infusion of prostacyclin reduces endothelial
damage after major surgery and AMI. Thus, a study is pertinent to investigate if prostacyclin infusion as a
therapeutic intervention reduces endothelial damage without compromising, or even improving, the hemostatic
competence in resuscitated cardiac arrest patients. Post-cardiac arrest patients frequently have a need for
vasopressor therapy (catecholamines) to achieve the guideline-supported blood pressure goals. To evaluate a
possible catecholamine interaction with the primary endpoints of this study, included patients will be randomized
into two different blood pressure goals within guideline-recommended targets.
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Methods/design: A randomized, placebo-controlled, double-blind investigator-initiated pilot trial in 40 out-of-
hospital-cardiac-arrest (OHCA) patients will be conducted. Patients will be randomly assigned to either the active
treatment group (48 hours of active study drug (iloprost, 1 ng/kg/min) or to the control group [placebo (saline)
infusion]. Target mean blood pressure levels will be allocated 1:1 to 65 mmHg or approximately 75 mmHg, which
gives four different permutations, namely: (i) iloprost/65 mHg, (ii) iloprost/75 mmHg, (iii) placebo/65 mmHg, and (iv)
placebo/75 mmHg. All randomized patients will be treated in accordance with state-of-the art therapy including
targeted temperature management.
The primary endpoint of this study is change in biomarkers indicative of endothelial activation and damage, [soluble
thrombomodulin (sTM), sE-selectin, syndecan-1, soluble vascular endothelial growth factor (sVEGF), nucleosomes] and
sympathoadrenal over activation (epinephrine/norepinephrine) from baseline to 48 hours post-randomization.
The secondary endpoints of this trial will include: (1) the hemostatic profile [change in functional hemostatic blood
test (thrombelastography (TEG) and whole blood platelet aggregometry (multiplate)) blood cell and endothelial
cell-derived microparticles]; (2) feasibility of blood pressure target intervention (target 90 %); (3) interaction of primary
endpoints and blood pressure target; (4) levels of neuron-specific enolase at 48 hours post-inclusion according to
blood pressure targets.
Discussion: The ENDO-RCA study is a pilot study trial that investigates safety and efficacy of low-dose infusion of
prostacyclin administration as compared to standard therapy in post-cardiac arrest syndrome patients.
Trial registration: Trial registration at ClinicalTrials.gov (identifier NCT02685618) on 18 February 2016.
Keywords: Out-of-hospital cardiac arrest (OHCA), Endothelial dysfunction, Prostacyclin
Background
Despite efforts during the last decades to optimize car-
diac arrest resuscitation techniques and post-cardiac ar-
rest care, mortality rates are still high [1]. Survival to
discharge rates from out-of-hospital cardiac arrest
(OHCA) varies among studies and regions [2–4] and
was reported in a recent systematic review to be 2, 6, 9
and 11 percent respectively for Asia, North America,
Europe and Australia [2] with half of cardiac arrest sur-
vivors suffering from cognitive impairment [5].
The high mortality rate of patients with initial return of
spontaneous circulation (ROSC) is in part due to a specific
pathophysiologic process known as the post-cardiac arrest
syndrome (PCAS). This term describes a global ischemia-
reperfusion injury in response to whole-body ischemia fol-
lowing successful resuscitation [1]. On a pathophysiologic
level, the ischemia-reperfusion injuries associated with
PCAS involve microcirculatory dysfunction [6], vascular
leakage with ensuing edema, and an increase in platelet
and leukocyte adhesion to the activated/injured endothe-
lium. The consequence of these injuries to the endothe-
lium results in a sepsis-like inflammatory response [7–9]
that ultimately determines patients’ outcome.
Patients suffering from acute critical illness display evi-
dence of excessive sympathoadrenal activation [10–14]
and there is emerging evidence that the normal “fight-or-
flight” response may become maladaptive and induce
organ damage [15, 16]. Thus, increasing levels of endogen-
ous catecholamines induce widespread dose-dependent
effects on the vascular system [16]. In high concentrations
catecholamines directly damage the endothelium [17, 18]
and promote hypocoagulability and hyperfibrinolysis in
the blood [19–21]. It is hypothesized [22] that the progres-
sive hypocoagulability and hyperfibrinolysis observed in
critically ill patients reflects an evolutionary adapted
response aiming at keeping the microvasculature open
in conditions with low flow, and inferred that the cat-
echolamine surge, through its opposite directed effects on
the endothelium and blood, is a critical driver of this
response (Fig. 1).
This hypothesis [22] was investigated in three different
types of patients characterized by acute critical illness.
The outcome of these studies displayed strong and inde-
pendent associations between circulating levels of cate-
cholamines and biomarkers of endothelial activation and
damage and outcome in trauma patients [23], in patients
with acute myocardial infarction (AMI) [13] and in pa-
tients with severe sepsis and septic shock [24]. Several
studies provide evidence of endothelial damage after suc-
cessful cardiac arrest resuscitation [6, 9, 25–27] and the
specific biomarkers investigated as endpoints for endothe-
lial damage and sympathoadrenal activation in this study
has recently been related to patient outcome in OHCA
patients [28]. In alignment with the hypothesis described,
it has been reported that patients resuscitated from car-
diac arrest display evidence of coagulopathy [6, 29–31]
and endothelial injury [25, 26, 32].
Current state-of-the art therapy for OHCA includes
general organ support and targeted temperature manage-
ment for up to 24 hours after admission in unconscious
Meyer et al. Trials  (2016) 17:378 Page 2 of 9
patients [33]. Therapeutic interventions directed toward
the damaged endothelium may improve outcome for pa-
tients with PCAS. Prostacyclin (prostaglandin I2, PGI2) is
an endogenous prostanoid which is formed and released
by endothelial cells with antiplatelet, vasodilatory and
cytoprotective properties [34]. Accordingly, prostacyclin is
expected to be beneficial by protecting and deactivating
the endothelium and by restoring vascular integrity in pa-
tients suffering from endothelial breakdown [35].
Prostacyclin is currently used for the treatment of critic-
ally ill patients with pulmonary hypertension [36] and crit-
ical limb ischemia due to its vasodilatory properties [37].
Former studies with critically ill patients that received
prostacyclin [35, 38] showed results reflecting a stabilizing
effect on the endothelium and hemostasis measured by
endothelial biomarkers and viscoelastic hemostatic assays.
These studies provide the rationale for the hypothesis that
prostacyclin may be beneficial as an endothelial rescue
treatment in patients suffering from endothelial break-
down such as after resuscitated cardiac arrest (RCA).
From a safety point of view, the low-dose infusion of pros-
tacyclin selected for this trial is lower than the recom-
mended dose for approved indications. The dosage
chosen for the current trial has previously been utilized
without reported significant adverse side effects [38–40].
Systemic blood pressure is part of the goals in most
post-cardiac arrest care protocols. Blood pressure goals
have not been specifically studied and the level of evidence
is generally low [41]. The recent update of the American
Heart Association continues to emphasize the necessity of
standardized goal-directed care but also acknowledges
that existing protocols include blood pressure targets
varying from 65 mmHg to as high as 80 mmHg in mean
arterial pressure [42]. Studies have found a significant
prevalence of impaired cerebral autoregulation post car-
diac arrest, and that some patients may need significantly
higher perfusion pressure to maintain cerebral blood flow
post cardiac arrest [43]. The recent guideline however
recommends a target blood pressure on 65 mmHg and
the use of catecholamines to achieve this pressure [42].
Blood pressure and exogeneous catecholamines may con-
sequently influence the effect of prostacyclin analogue
(iloprost) on the endothelium.
Aim
This pilot study aims to investigate (1) the relationship be-
tween the stress response and endothelial damage, (2) if
prostacyclin treatment reduces endothelial damage (and
organ failure) in RCA patients, (3) the effect of prostacyclin
treatment on hemostasis, and (4) if blood pressure target
(65 mmHg or 75 mmHg) during the intensive care unit
(ICU) stay will influence the endothelial response to the
study drug and levels of neuron-specific enolasis at 48 hours.
Methods/design
Design
This is a single-center, randomized (1:1, active:placebo),
placebo-controlled, double-blind investigator-initiated pilot
Fig. 1 A systems biology perspective on vascular homeostasis in critical illness. Schematic illustration of the changes in the vascular system
(circulating blood, vascular endothelium) with increasing disease (ischemia-reperfusion, trauma, sepsis, etc.) severity and sympathoadrenal
activation (circulating catecholamines) evaluated by plasma-based (APTT, INR, PT) and functional whole blood-based (TEG) coagulation tests.
Progressive endothelial activation and damage is accompanied by concurrent progressive hypocoagulability in the circulating blood. We infer
(Johansson and Ostrowski) that the circulating catecholamine level dose-dependently promotes a switch from hyper- to hypocoagulability and
hyperfibrinolysis in the blood to keep the progressively more procoagulant microvasculature open. From Johansson & Ostrowski [22]
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study in 40 out-of-hospital-cardiac-arrest (OHCA) patients
investigating iloprost safety and efficacy. Furthermore, the
impact of exogenous catecholamines and blood pressure
targets is investigated by randomization of target blood
pressures to 65 mmHg and approximately 75 mmHg.
Blood pressure levels will be allocated 1:1 in a 2 × 2 factorial
design, providing four different permutations: (i) iloprost/
65 mHg, (ii) iloprost/75 mmHg, (iii) placebo/65 mmHg,
and (iv) placebo/75 mmHg with ten patients in each group.
Withdrawal
Participation in the ENDO-RCA trial is voluntary. Pa-
tients, relatives or scientific guardians are free to discon-
tinue the trial at any time. The treating physician can
discontinue patient participation in the trial if the phys-
ician suspects that participation affects the patient’s safety.
If there is medical reason for the withdrawal, the patient
should be followed medically until the condition has stabi-
lized or terminated. The reason for withdrawal should be
recorded in the patient’s case report form (CRF).
If consent for patient participation is declined by the
patients’ next of kin, the patients’ general practitioner or
the patient him/herself, blood samples will be destroyed
according to laboratory standard operating procedure.
Collected data, laboratory notes, and sample analysis re-
sults will be deleted. If consent is declined during study
drug administration, the drug-infusion will be termi-
nated. In case a patient or next of kin make a withdrawal
of consent, the party will be asked for permission to use
data obtained prior to withdrawal and to obtain data for
the primary outcome measure. If this is achieved, the pa-
tient will be included in the final analyses. If the patient
declines, all data from that patient will be destroyed. All
patients who withdraw from the trial for any reason and
at any time should have an end-of-trial examination. Pa-
tients will be examined for any status changes that re-
quire further follow-up. All withdrawn patients will be
followed up as the remaining patients in the trial. If con-
sent is withdrawn, the person making the withdrawal
will be asked for permission to follow up for 90 days
after randomization.
Inclusion criteria
Participants in the trial must be adult patients (≥18 years
of age) with OHCA of presumed cardiac cause admitted
to the Department of Cardiology, 2143, Rigshospitalet,
Copenhagen. Patients must be unconscious (Glasgow
coma scale (GCS) <8) and have sustained ROSC (chest
compressions have not been required for 20 consecutive
minutes and signs of circulation persist). Temperature
management is indicated.
The inclusion criteria enclose a group of critically ill
patients that previously have been associated with coag-
ulopathy and endothelial injury [6, 25, 26, 29–32] and
hence, include patients with likelihood of deriving bene-
fit from the intervention. In recent studies with patients
receiving low-dose prostacyclin, the results reflects a
stabilizing effect on the endothelium by lower levels of
biomarkers indicative of endothelium activation and
damage [35, 38]. The results suggest that patients resus-
citated from cardiac arrest could benefit from low-dose
infusion of prostacyclin by protecting and deactivating
the endothelium and by restoring vascular integrity.
Exclusion criteria
Patients fulfilling the following criteria will be excluded:
(1) conscious patients (obeying verbal commands equal to
a Glasgow Coma Score of 8 or more); (2) females of child-
bearing potential [unless a negative human chorionic go-
nadotropin (HCG) test can rule out pregnancy]; (3)
patients weighing more than 135 kg; (4) in-hospital car-
diac arrest (IHCA); (5) OHCA of presumed non-cardiac
cause, e.g., after trauma or dissection/rupture of major ar-
tery OR cardiac arrest caused by initial hypoxia (i.e.,
drowning, suffocation, hanging); (6) known congenital
bleeding diathesis (antithrombotic, anticoagulation medi-
cations are allowed); (7) suspected or confirmed acute
intracranial bleeding; (8) suspected or confirmed acute
stroke; (9) unwitnessed asystole; (10) known limitations in
therapy and do-not- resuscitate order; (11) known dis-
ease-making 180-day survival unlikely; (12) known
pre-arrest cerebral performance category (CPC) of 3 or 4;
(13) >4 hours (240 minutes) from ROSC to screening; (14)
systolic blood pressure <80 mmHg in spite of fluid loading/
vasopressor and/or inotropic medication/intra-aortic bal-
loon pump/axial flow device [If the systolic blood pressure
(SBP) is recovering during the inclusion window the patient
can be included.]; (15) temperature on admission <30 °C;
(16) known allergy to prostacyclin analogues.
The endothelial protective effect of the study drug is be-
lieved to alleviate reperfusion injury and reduce progres-
sive brain injury by apoptosis after OHCA. Non-comatose
patients (being awake at admission or a short time to
post-arrest awakening) have been related to better long-
term cognitive functioning [5]. These exclusion criteria
will enable exclusion of patients most unlikely to survive
the intervention period of 48 hours and exclude patients
with characteristics that might bias the outcomes.
Randomization
Screening of patients to the trial will be performed by a
cardiologist on duty at the Departmentof Cardiology,
Rigshospitalet. A screening log will be kept at the site to
determine the number of patients meeting the inclusion
criteria, eligible patients, patients with consent who are
randomized, and reasons why potential eligible patients
were not enrolled.
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Patients will only be enrolled after informed consent,
but as the treatment has to be initiated earliest possible
after the out-of-hospital cardiac arrest diagnosis, i.e., at a
time point where patients are temporarily incompetent
and the next of kin may not have reached the hospital
yet and it may be outside opening hours of the general
practitioner, it may be impossible to obtain surrogate
consent from next of kin and general practitioner. In this
situation, patients may be included after proxy consent
by two independent physicians. The consent form must
be signed by the participant or legally acceptable surro-
gate and by the investigator seeking the consent.
Randomization will be performed by a web-based site
administered by a webmaster unrelated to the trial. Each
patient will be assigned a unique trial and randomization
number. Randomization will be generated into dynamic
blocks and stratified for the clinical trial site. Patients
will be randomized to receive either active treatment or
placebo and target blood pressure of 65 or approxi-
mately 75 mmHg. A randomization list will be held by
webmaster at the Departtment of Cardiology, which will
be available to investigator after the completion of the
trial. Emergency code breaking will be available and ad-
ministered by the webmaster.
Intervention
A 1:1 randomized stratification for active study drug or
placebo infusion and blood pressure target for 48 hours.
Patients in both randomization groups will be treated in
accordance with state-of-the-art therapy including tar-
geted temperature management. Interventions are con-
sidered emergency procedures and study drug infusion
should be commenced as soon as possible after sus-
tained ROSC, screening and randomization. Patients
with active treatment will receive a low-dose prostacyc-
lin infusion whilst the placebo group receives a dummy
saline infusion for 48 hour in a total of 40 patients. The
active treatment (n = 20 patients) will consist of continu-
ous administration of i.v. infusions of 1.0 ng/kg/min of ilo-
prost for 48 hours. Patients in the placebo group (n = 20
patients) will receive dummy saline infusion at a volume
comparable to active treatment and will otherwise be
treated exactly as active patients. This dosing regimen
was chosen since intravenous doses of prostacyclin
0.5–2.0 ng/kg/min have been reported to be successful at
achieving endothelial modulating/preserving effect with
no significant hemodynamic or platelet aggregation com-
plications [39, 40, 44]. The chosen dose of 1.0 ng/kg/min
has demonstrated beneficial effects on vascular integrity
in critically ill patients when administered for 3 days [40].
The 1.0 ng/kg/min dose is five- to tenfold higher than the
normal endogenous production of prostacyclin from the
healthy endothelium and is not expected to induce vaso-
dilation and hypotension [45].
For investigation of the impact of blood pressure goals
a supplementary randomization of target blood pressure
will be made. Before the patient arrives at the ICU a
randomization of using one of two identical blood
pressure modules have been made, one being offset
by approximately −10 mmHg. The blood pressure
number displayed on the monitor will therefore be
10 mmHg lower that the actual blood pressure, thus
keeping this intervention blinded to care providers,
patients and relatives.
Biomarkers of endothelial damage, [soluble thrombo-
modulin (sTM), sE-selectin, syndecan 1, soluble vascular
endothelial growth factor (sVEGF), nucleosomes] and
sympathoadrenal overactivation (epinephrine/norepineph-
rine) together with functional hemostatic assays [thrombe-
lastography (TEG) and whole blood platelet aggregometry
(multiplate)] and blood cell- and endothelial cell-derived
microparticles will be investigated together with clinical
outcome measures at 6, 24, 48, 72 and 96 hours.
The study drug will be supplied by the sponsor, Pär I.
Johansson MD, DMSc, MPA, Section for Transfusion
Medicine, Capital Region Blood Bank, Rigshospitalet,
2034, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Blinding
To circumvent selection bias, researchers and health care
personnel, will be blinded to the treatment assignment.
Furthermore, to avoid investigator, health care staff and
patient performance and detection bias, patients will be
randomized to receive either iloprost (Ilomedin®, Bayer
AG, Leverkusen, Germany) or placebo similar in color,
consistency, and volume. The calibration of the identical
blood pressure modules will be performed by a technician
with no affiliation to the intensive care unit, thus enabling
blinding of study personnel, care providers, patients and
relatives. The blood pressure target intervention will be al-
located according to inclusion number at initial screening
and randomization of the patient. Blinded study and non-
study personnel will record clinical data, analyze blood
samples and perform neurocognitive assessments. All ran-
domized patients that have received iloprost will continue
to be included in the assessments of its safety and efficacy.
We expect no loss to follow-up in hospital, provided that
this pilot study takes place in a hospital setting where the
majority of the outcomes will be evaluated. After dis-
charge from the hospital, attrition bias will be avoided by
following measures: family member contact information
will be requested in case patient contact is unattainable or
if the patient is incapacitated to provide information; the
study coordinator will have continuous contact with the
patient and family member during the ICU stay and at the
time of ICU discharge to emphasize following contact (30,
90 and 180 days); the patient and family member will be
notified of upcoming interviews in writing; public records
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The primary objective of this pilot study is safety and effi-
cacy of low-dose iloprost administration in addition to
standard therapy, as compared to standard therapy alone,
in post-cardiac arrest syndrome patients. The selection of
primary outcome of this study is biochemical change with
markers such as change in biomarkers indicative of
endothelial activation and damage (sTM, sE-selectin,
syndecan-1, sVEGF, nucleosomes) and sympathoadrenal
overactivation (epinephrine/norepinephrine).
Secondary endpoints
The secondary endpoints of this trial will include: (1) the
hemostatic profile (change in functional hemostatic
blood test [thrombelastography (TEG) and whole blood
platelet aggregometry (multiplate) blood cell- and endo-
thelial cell-derived microparticles]; (2) feasibility of blood
pressure target intervention (target 90 %); (3) interaction
of primary endpoints and blood pressure target; (4) levels
of neuron-specific enolase at 48 hours post- inclusion ac-
cording to blood pressure targets.
Tertiary endpoints
The tertiary endpoints will include: (1) days of vasopres-
sor, ventilator, and renal replacement therapy post-
randomization; (2) changes in sequential organ failure
assessment (SOFA) score from baseline to 48 hours
and day 4 post-randomization; (3) neurological function
graded by modified Rankin Scale (mRS) and cerebral per-
formance category (CPC) at 180 days; (4) severe bleeding
[intracranial or clinical bleeding with the use of three red
blood cell (RBC) units or more/24 hours]; (5) use of blood
products (in ICU) post-randomization; (6) difference in
day 7-, 30-, 90- and 180-day mortality between patients
receiving active treatment (iloprost) and placebo; (7) esti-
mated glomerular filtration rate (eGFR) and urine output
on day 2 and 3; and (8) need for renal replacement ther-
apy during the ICU stay.
Assessment and registration of serious adverse reactions
(SARs), serious adverse events (SAE) and suspected
unexpected serious adverse reactions (SUSARs)
The serious adverse reactions predominantly reported in
relation to administration of the study drug (iloprost) are
allergic reactions, thrombosis, and bleeding. Occurrence
of adverse events and adverse reactions will be monitored
and recorded daily in the case report form (CRF).
Serious adverse reactions (SARs) and serious adverse
events (SAE) will be reported immediately to the sponsor
for causality evaluation and determination of possible
suspected unexpected serious adverse reactions (SUSAR).
The good clinical practice (GCP) unit will be given access
to blinded data in the CRF to enable continuous monitor-
ing. During the trial, the investigator will send a yearly
report on the occurrence of SARs to the Danish Health
and Medicines Authority and Ethics Committee.
Suspected unexpected serious adverse reactions (SUS-
ARs) will be defined as serious adverse reactions not
described in iloprost summary for product characteristics.
SUSARs will be reported by the sponsor according to
regulation directly to the Danish Health and Medicines
Authority and Ethics Committee. SUSARs, which are fatal
or life-threatening, will be reported as soon as possible
and no later than 7 days after the sponsor is informed.
Any other SUSARs must be reported to the Danish Health
and Medicines Authority and Ethics Committee no later
than 15 days from report of adverse effects.
Statistical analysis
Sample size
A total 40 of patients will be recruited in a 1:1 ratio acti-
ve:placebo. Blood pressure levels will be allocated 1:1 in
a 2 × 2 factorial design, providing four different permuta-
tions: (i) iloprost/65 mHg, (ii) iloprost/75 mmHg, (iii)
placebo/65 mmHg, and (iv) placebo/75 mmHg with ten
patients in each of the four groups.
The number of patients participating is based on a
power calculation. The calculation is based on data col-
lected in a randomized study performed by Johansson et
al. (manuscript in preparation), investigating the effect
of prostacyclin infusion (1 ng/kg/min) on hemostasis
and the endothelium in patients undergoing Whipple sur-
gery. The primary biomarker of interest is thrombomodu-
lin, which is used for the power calculation: the increase in
circulating thrombomodulin differed significantly among
the active ((mean ± SD) 0.53 ± 0.52 ng/ml) and placebo
(2.14 ± 2.19 ng/ml) group post-surgery (p = 0.046). To de-
tect this difference two-sided with a power of 0.85 (1-beta)
and alpha of 0.05 requires n = 19 patients in each group,
respectively (STATA IC 14.1). Twenty patients will be in-
cluded in each group. All patients that receive low-dose
prostacyclin infusion will be included. A total 40 patients
will be recruited in a 1:1 ratio active:placebo. Patients who
drop out or are withdrawn for any reason before day 4 will
be replaced.
Statistical methods
This is a pilot trial and thus all statistical tests should be
considered to be exploratory. Descriptive statistics will be
calculated for all endpoints. All summary statistics of con-
tinuous variables will include: n, mean with standard devi-
ation, median with min/max and interquartile ranges. All
summary statistics of frequency tables will include n, %
and N, where N is the total number of patients recorded
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values in the corresponding group. The difference be-
tween treatment groups for continuous data will be evalu-
ated using analysis of variance (mixed model) followed by
post hoc pair-wise comparisons of means. Furthermore,
delta values (numerical change in variables between time
points) within and between groups will be compared by
paired (Wilcoxon signed-rank test) and non-paired
(Mann-Whitney U test) nonparametric tests. The differ-
ence between treatment groups for categorical data will be
evaluated using McNemar’s test (change over time), fre-
quency tables and chi-square statistics. The difference
between treatment groups for continuous data will be
evaluated using analysis of variance (mixed model)
followed by post hoc pair-wise comparisons of means.
Nonparametric tests, Wilcoxon rank-sum test, will be
used if the assumption of normality is not fulfilled.
Mortality will be evaluated applying survival statistics, i.e.,
Kaplan Meier plots and log-rank test and Cox propor-
tional hazards models. Data will be tabled and summa-
rized descriptively.
Pilot study
ENDO-RCA is a comprehensive exploratory framework
that investigates the possible beneficial role of prostacyc-
lin on endothelial integrity in patients suffering post-
cardiac arrest syndrome. Several studies in the OHCA
population have been successfully conducted at the trial
site (ICU at the Department of Cardiology, Rigshospita-
let, Copenhagen) and the timeline for patient enrollment
is anticipated to extend over 6 months. This pilot study
has no planned interim analyses and the trial will not be
extended. The results from ENDO-RCA, if positive, will
form a basis for grant applications from the European
Commission (HORIZON 2020) and the National Insti-
tutes of Health (NIH) enabling large-scale multicenter
randomized clinical trials.
Discussion
The continuously low survival-to-discharge rates after car-
diac arrest necessitates further exploration of resuscitation
techniques and post-cardiac arrest care. This study will at-
tempt to address and target the harmful effects of systemic
ischemia and reperfusion in patients with PCAS.
The excessive sympathoadrenal activation presented
by critically ill patients [10–14] is hypothesized [22] to
be a critical driver of endothelial damage [17, 18], pro-
gressive hypocoagulability and hyperfibrinolysis in the
vascular system [19–21]. The stress response in critically
ill patients has been linked to the development of endo-
thelial damage and coagulopathy in three patient groups
(trauma patients, AMI patients and severe sepsis and
septic shock patients) of which all revealed strong and
independent associations between circulating levels of
catecholamines and biomarkers of endothelial activation
and damage and outcome, demonstrating that patients
presenting with severe endothelial dysfunction suffer
from higher mortality rates as compared to patients
without endothelial complications [13, 23, 24].
Prostacyclin infusion is expected to be beneficial for
PCAS patients by protecting and deactivating the endo-
thelium and by restoring vascular integrity in patients
suffering from endothelial breakdown [34]. In a study of
critically ill patients needing renal replacement therapy,
patients receiving prostacyclin as anticoagulant in the
dialysis filter had lower mortality than patients receiving
heparin as anticoagulant [35]. The results were specu-
lated to be due to a spillover effect of prostacyclin to the
systemic circulation, reflecting a stabilizing effect on the
endothelium. As a continuation of this finding, a ran-
domized controlled pilot study was performed in pa-
tients undergoing percutaneous coronary intervention
(PCI). The study showed that patients randomized to
receive infusion of low-dose (1 ng/kg/min) prostacyclin
after coronary stenting improved endothelial functional-
ity evidenced by lower levels of the soluble endothelial
biomarker sE-selectin [38]. Finally, a randomized con-
trolled pilot study performed on patients with pancreatic
cancer undergoing Whipple surgery, known to experi-
ence capillary leakage due to endothelial disintegration,
patients allocated to infusion of low-dose prostacyclin
presented significantly improved endothelial integrity
again as evaluated by lower sE-selectin as compared to
patients receiving placebo (Johansson PI. Clinical trial
ET-abdominal, manuscript in preparation). This body of
evidence indicates that low-dose intravenous prostacyc-
lin may be beneficial as an endothelial rescue treatment
in patients suffering from endothelial breakdown. The
low-dose infusion of prostacyclin selected for this trial
(1.0 ng/kg/min) is five- to tenfold higher than the
normal endogenous prostacyclin production. However,
the dose is lower than the recommended dose for
approved indications and has been reported to be with-
out significant adverse side effects [38–40].
Post-cardiac arrest patients most often have a need
for vasopressor infusions (catecholamines) to achieve
the guideline supported goal of mean arterial artery
pressure of approximately 65 mmHg. Subsequently a
possible interaction with the primary endpoints may
exist. This will be evaluated by targeting two different
goals (65 mmHg or approximately 75 mmHg) within
the interval of blood pressure goals supported by the
recent guidelines [42].
This study will target high-risk critically ill patients, suf-
fering global ischemia-reperfusion injury, with likelihood
to derive benefit from the immediate intervention of low-
dose prostacyclin infusion. The included patient group
provides a pertinent background to investigate circulating
catecholamines, endothelial damage and coagulopathy in
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low/ceased blood flow and the protective and stabilizing
effects of prostacyclin on the endothelium.
Trial status
Inclusion of patients is scheduled to commence February
2016 and expected to be completed by September 2016.
This research project is a multidisciplinary collaboration
between laboratory and clinical medical expertise encom-
passing a prospective, randomized, double-blinded pilot
study in PCAS patients, and will be conducted with estab-
lished partners in the Blood Bank and in the ICU at the
Department of Cardiology, Rigshospitalet, Copenhagen.
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